Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women

Dong-A ST Co., Ltd.149 enrolled

Overview

To evaluate the effect of 1 year of risedronate treatment on the prevention of bone loss after denosumab discontinuation in denosumab-treated post-menopausal osteoporosis for a year

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

149

Conditions

Postmenopausal Osteoporosis

Interventions

Risedronate Sodium 35 MG [Actonel]DRUG

Risendronate Sodium Tab. 35mg, orally, once weekly

Calcium Vitamin D combinationDRUG

orally, once daily for concomitant drug

Eligibility

Sex: FEMALEMin age: 50 YearsMax age: 80 Years

Medical Language ↔ Plain English

Main Inclusion Criteria: 1. Postmenopausal women 2. Patients diagnosed with postmenopausal osteoporosis and administered denosumab for 1 year Main Exclusion Criteria: 1. Any contraindication to risedronate 2. Those evaluated as inappropriate at the discretion of the investigator

Locations (1)

Severance Hospital

Seoul, Seodaemun-gu, South Korea

Outcomes

Primary Outcomes

Percent change from baseline in lumbar spine bone mineral density (LS BMD) at 1 year (%)

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.